Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Renin-Angiotensin System Clear all

Conditions: Obesity, Vitamin D Deficiency, Hypertension
Interventions: Vitamin D (cholecalciferol); Dietary Supplement
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 64 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypotension, Anesthesia
Interventions: Methohexital, Propofol; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Kidney, Polycystic
Interventions: Lisinopril, Telmisartan, Placebo, Standard Blood Pressure Control, Low Blood Pressure Control; Drug · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 15 Years to 64 Years
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 7
States / cities: Aurora, Colorado • Atlanta, Georgia • Kansas City, Kansas + 3 more

Conditions: Diabetic Nephropathy
Interventions: Addition of furosemide 20 mg oral bid to baseline regimen; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 2
States / cities: Santa Clara, California • Stanford, California

Conditions: Healthy Volunteer
Interventions: aleglitazar, placebo, ibuprofen; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 40 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Sepsis, Acute Kidney Injury Due to Sepsis, Acute Kidney Injury (Nontraumatic)
Interventions: Not listed
Lead sponsor: Northwell Health; Other
Eligibility: 1 Day to 18 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Chronic Kidney Disease, Type 2 Diabetes
Interventions: Finerenone, Semaglutide, Lotensin, Capoten, Enalapril, Monopril, Lisinopril, Univasc, Aceon, Accupril, Altace, Mavik, Edarbi, Atacand, Avapro, Cozaar, Benicar, Micardis, Diovan, Invokana, Farxiga, Jardiance, Ertugliflozin, Brenzavvy, Sotagliflozin; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 84 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Renal Transplant, Renin-Angiotensin System, Rejection Acute Renal, Rejection Chronic Renal, Rejection of Renal Transplant
Interventions: Renal Transplantation; Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 1 Year to 20 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Arterial Stiffness, Renin Angiotensin Aldosterone System, Orthostatic Hypotension, Spinal Cord Injury, Hypotension
Interventions: Spinal Cord Injury; Other
Lead sponsor: James J. Peters Veterans Affairs Medical Center; Federal
Eligibility: 21 Years to 70 Years
Enrollment: 33 participants
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Hyperparathyroidism
Interventions: Lisinopril; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV-infection
Interventions: Angiotensin II Infusion; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus Type 2
Interventions: aleglitazar, lisinopril, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Chula Vista, California • Omaha, Nebraska • Dallas, Texas + 1 more

Conditions: Acute Decompensated Heart Failure, Congestive Heart Failure
Interventions: Aliskiren, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,639 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 37
States / cities: Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 29 more

Conditions: Diabetic Nephropathy, Chronic Kidney Disease
Interventions: Zemplar (paricalcitol) capsules, Placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 20 Years and older
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 27
States / cities: Phoenix, Arizona • Fountain Valley, California • Yuba City, California + 21 more

Conditions: Chronic Kidney Disease, Secondary Hyperparathyroidism
Interventions: Contrast Enhanced Ultrasonography; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Cardiac Surgery With Cardiopulmonary Bypass
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hypertension, Left Ventricular Hypertrophy, Left Ventricular Dysfunction, Left Atrial Dilatation, Left Ventricular Diastolic Dysfunction, Kidney Diseases, Kidney Injury, Kidney Dysfunction, Sodium Urine High, Blood Pressure Disorders, Uric Acid Retention, Angiotensin Hypertension, Autonomic Dysfunction, Autonomic Imbalance, Pediatric Kidney Disease, Pediatric Obesity, Proteinuria, Albuminuria
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 7 Years to 18 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Microalbuminuria
Interventions: benazepril; Drug
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 18 Years to 70 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypertension
Interventions: Lisinopril, Atenolol; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension, Metabolic Syndrome
Interventions: Aliskerin/Valsartan and Rampiril; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Obesity, Prehypertension, Hypertension
Interventions: Clonidine, Hydrochlorothiazide, Placebo; Drug
Lead sponsor: Gary L. Pierce; Other
Eligibility: 18 Years to 79 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Coronary Artery Disease (CAD), Coronary Atherosclerosis
Interventions: Placebo, Aliskiren; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 35 Years and older
Enrollment: 613 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 54
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 48 more

Conditions: Pediatric Disorder, Pediatric Obesity, Primary Hypertension
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 5 Years to 17 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Atrial Fibrillation
Interventions: no drug, start cozaar, continue cozaar; Other · Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Vitamin D Supplementation Reduces Renin-Angiotensin System Activity in Obesity

Methohexital v Propofol as General Anesthetic in Patients on ACEIs or ARBs

HALT Progression of Polycystic Kidney Disease Study A

Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.

A Study of Aleglitazar in Combination With Ibuprofen in Healthy Volunteers

Renin Angiotensin Aldosterone System In Septic Kids

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)

RAAS and Arterial Stiffness in SCI

The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study

Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV

A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril

Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure

The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors

Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease

Evaluation of Plasma Renin Concentrations in Cardiac Surgery

Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)

Low Dose Versus Aggressive Inhibition of the Renin-Angiotensin-Aldosterone (RAS) to Treat Microalbuminuria

Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study

The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome

Vascular Dysfunction in Human Obesity Hypertension

Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients

Pediatric Primary Hypertension and the Renin-Angiotensin System (PHRAS)

Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition)